Dashboard
1
Weak Long Term Fundamental Strength with a 340.47% CAGR growth in Operating Profits over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 6,785.00 times
- The company has reported losses. Due to this company has reported negative ROE
2
With ROE of 10.09%, it has a Very Expensive valuation with a 2.16 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
EUR 23,669 Million ()
21.00
NA
16.68%
0.37
10.09%
2.16
Revenue and Profits:
Net Sales:
5,097 Million
(Quarterly Results - Dec 2025)
Net Profit:
393 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
3.25%
0%
3.25%
6 Months
2.13%
0%
2.13%
1 Year
-1.72%
0%
-1.72%
2 Years
29.27%
0%
29.27%
3 Years
54.31%
0%
54.31%
4 Years
-6.29%
0%
-6.29%
5 Years
-47.26%
0%
-47.26%
Koninklijke Philips NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
608.36%
EBIT Growth (5y)
340.47%
EBIT to Interest (avg)
1.97
Debt to EBITDA (avg)
6,127.67
Net Debt to Equity (avg)
0.55
Sales to Capital Employed (avg)
0.77
Tax Ratio
25.47%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.12%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
2.16
EV to EBIT
17.02
EV to EBITDA
10.14
EV to Capital Employed
1.82
EV to Sales
1.58
PEG Ratio
0.09
Dividend Yield
16.68%
ROCE (Latest)
10.70%
ROE (Latest)
10.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 6 Foreign Institutions (0.16%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
5,097.00
5,044.00
1.05%
Operating Profit (PBDIT) excl Other Income
926.00
0.00
Interest
109.00
0.00
Exceptional Items
-91.00
0.00
Consolidate Net Profit
393.00
-476.00
182.56%
Operating Profit Margin (Excl OI)
126.90%
0.00%
12.69%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 1.05% vs 0.00% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 182.56% vs -1,112.77% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
17,834.00
18,021.00
-1.04%
Operating Profit (PBDIT) excl Other Income
2,676.00
2,397.00
11.64%
Interest
290.00
288.00
0.69%
Exceptional Items
-275.00
-349.00
21.20%
Consolidate Net Profit
900.00
-841.00
207.02%
Operating Profit Margin (Excl OI)
92.10%
68.50%
2.36%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -1.04% vs -0.81% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 207.02% vs -85.24% in Dec 2024
About Koninklijke Philips NV 
Koninklijke Philips NV
Pharmaceuticals & Biotechnology
Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
Company Coordinates 
Company Details
Breitner Center, Amstelplein 2 , AMSTERDAM None : 1096 BC
Registrar Details






